5[1] Chu SY， Sennello LT， Bunnell ST， et al. Pharmacokinetics of clarithromycin， a new macrolide， after single ascending oral dose[J]. Antimicrob Agents Chemother， 1992， 36: 2 447.
6[2] Hardy DJ， Swanson RN， Rode RA， et al. Enhancement of the in vitro and in vivo activities of clarithromycin against haemophilus influenzae by 14－ hydroxy－ clarithromycin， ts major metabolite in humans[J]. Antimicrob Agents Chemother， 1990， 34: 1 407.
7[3] Parish LC， Clarithromycin study group. Clarithromycin in the treatment of skin and skin structure infections:two multicenter clinical studies[J]. Int J Dermatol， 1993， 32（ 7） : 528.
8[4] Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients wich lower respiratory tract infections[J]. J Antimicrob Chemother， 1993， 31: （ Suppl E):137.
9[5] Muller O. Comparison of azithromycin versus clarithromycin in the trentment of patients with upper respiratory tract infections[J]. J Antimicrob Chemother， 1993，31:（ Suppl E） : 137.
10Kirst HA, Sides GD. Minirevews : New directions for macrolide atibiotics : structutre modification and in vitro activity,Antimicrob Agents Chemother,1989,33:1413.
